Table 2.
Viable cultures of B16 MRD
|
||
---|---|---|
First-line therapy inducing MRD | −TNFα | +TNFα |
B16tk/GCV | 0/7 | 5/5 |
B16tk/i.t. Reovirus | 1/9 | 4/4 |
B16ova/OT-I | 0/7 | 5/7 |
B16tk/Pmel/VSV-hgp100 | 1/4 | 3/3 |
Total | 2/27 (7%) | 17/19 (89%) |
Viable cultures of B16 MRD
|
||
---|---|---|
First-line therapy inducing MRD | −TNFα | +TNFα |
B16tk/GCV | 0/7 | 5/5 |
B16tk/i.t. Reovirus | 1/9 | 4/4 |
B16ova/OT-I | 0/7 | 5/7 |
B16tk/Pmel/VSV-hgp100 | 1/4 | 3/3 |
Total | 2/27 (7%) | 17/19 (89%) |